Selected article for: "Hubei province and million people"
Author: Jan, Hasnain; Faisal, Shah; Khan, Ayyaz; Khan, Shahzar; Usman, Hazrat; Liaqat, Rabia; Shah, Sajjad Ali
Title: COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
  • Cord-id: 03pd9jtn
  • Document date: 2020_4_26
    • ID: 03pd9jtn
    Snippet: An epidemic of extreme respiratory deterrence, pneumonia and shortness of breath, the SARS-CoV-2 viral infection began in Wuhan, Hubei Province, China in December 2019, and rapidly spread across China and beyond, with human to human transmission. On February 12, 2020, World Health Organization officially named the new coronavirus disease as coronavirus disease 19 (COVID-19). Most COVID-19 patients were diagnosed with pneumonia and many were treated using Chinese medicines and other secondary the
    Document: An epidemic of extreme respiratory deterrence, pneumonia and shortness of breath, the SARS-CoV-2 viral infection began in Wuhan, Hubei Province, China in December 2019, and rapidly spread across China and beyond, with human to human transmission. On February 12, 2020, World Health Organization officially named the new coronavirus disease as coronavirus disease 19 (COVID-19). Most COVID-19 patients were diagnosed with pneumonia and many were treated using Chinese medicines and other secondary therapies. As of April 22, 2020, the total figure of infected patients has crossed 2.6 million people worldwide with over 180,000 deaths and 700,000 patients that have recovered. Preliminary reports suggest that certain drugs, such as chloroquine and antiviral nucleotide analogues such as remdesivir, which inhibit viral replication, can target the new coronavirus, although their usefulness in the clinic is still under debate. An expert US committee developed the US NIH guidelines for COVID-19 treatment, which was just released and will be regularly updated. This manuscript reviews the epidemiology, etiology, mortality, COVID-19 clinical symptoms, and potential therapeutic drugs, while highlighting the seriousness and damage-induced by SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • active epidemic and acute respiratory infection: 1
    • acute cardiac injury and additional information: 1
    • acute cardiac injury and long duration: 1
    • acute cardiac injury and lopinavir ritonavir: 1, 2, 3, 4
    • acute cardiac injury and low mortality: 1
    • acute cardiac injury and lung function: 1, 2
    • acute cardiac injury and lung include: 1
    • acute cardiac injury shock and lopinavir ritonavir: 1, 2
    • acute kidney injury and additional information: 1, 2, 3
    • acute kidney injury and long duration: 1
    • acute kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute kidney injury and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute kidney injury and lung function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress syndrome and additional information: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and adenosine analogue: 1
    • acute respiratory distress syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25